These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 23065272)

  • 1. Potential of human γδ T cells for immunotherapy of osteosarcoma.
    Li Z
    Mol Biol Rep; 2013 Jan; 40(1):427-37. PubMed ID: 23065272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of zoledronate on the cytotoxicity of γδ T cells from PBMCs of osteosarcoma patients against osteosarcoma].
    Li Z; Tang J; Sun L; Ye Z
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Jan; 29(1):6-9. PubMed ID: 23294710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decitabine Enhances Vγ9Vδ2 T Cell-Mediated Cytotoxic Effects on Osteosarcoma Cells
    Wang Z; Wang Z; Li S; Li B; Sun L; Li H; Lin P; Wang S; Teng W; Zhou X; Ye Z
    Front Immunol; 2018; 9():1239. PubMed ID: 29910819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
    Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
    Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Payload-delivering engineered γδ T cells display enhanced cytotoxicity, persistence, and efficacy in preclinical models of osteosarcoma.
    Fowler D; Barisa M; Southern A; Nattress C; Hawkins E; Vassalou E; Kanouta A; Counsell J; Rota E; Vlckova P; Draper B; De Mooij T; Farkas A; Brezovjakova H; Baker AT; Scotlandi K; Manara MC; Tape C; Chester K; Anderson J; Fisher J
    Sci Transl Med; 2024 May; 16(749):eadg9814. PubMed ID: 38809963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IFN-γ enhances HOS and U2OS cell lines susceptibility to γδ T cell-mediated killing through the Fas/Fas ligand pathway.
    Li Z; Xu Q; Peng H; Cheng R; Sun Z; Ye Z
    Int Immunopharmacol; 2011 Apr; 11(4):496-503. PubMed ID: 21238618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro potency, in vitro and in vivo efficacy of liposomal alendronate in combination with γδ T cell immunotherapy in mice.
    Hodgins NO; Al-Jamal WT; Wang JT; Parente-Pereira AC; Liu M; Maher J; Al-Jamal KT
    J Control Release; 2016 Nov; 241():229-241. PubMed ID: 27664328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-γδ TCR antibody-expanded γδ T cells: a better choice for the adoptive immunotherapy of lymphoid malignancies.
    Zhou J; Kang N; Cui L; Ba D; He W
    Cell Mol Immunol; 2012 Jan; 9(1):34-44. PubMed ID: 21666706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Potential of Ex Vivo Expanded γδ T Cells against Osteosarcoma Cells.
    Ko Y; Jeong YH; Lee JA
    Cells; 2022 Jul; 11(14):. PubMed ID: 35883606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Amplification of γδ T cells in PBMCs of healthy donors and osteosarcoma patients stimulated by zoledronate].
    Li ZX; Sun LL; Cheng RL; Sun ZW; Ye ZM
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2012 Aug; 28(8):822-4. PubMed ID: 22863589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gammadelta T cells as immune effectors against high-grade gliomas.
    Lamb LS
    Immunol Res; 2009; 45(1):85-95. PubMed ID: 19711198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive immunotherapy of lung cancer with immobilized anti-TCRgammadelta antibody-expanded human gammadelta T-cells in peripheral blood.
    Kang N; Zhou J; Zhang T; Wang L; Lu F; Cui Y; Cui L; He W
    Cancer Biol Ther; 2009 Aug; 8(16):1540-9. PubMed ID: 19471115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Celastrol increases osteosarcoma cell lysis by γδ T cells through up-regulation of death receptors.
    Li Z; Zhang J; Tang J; Wang R
    Oncotarget; 2016 Dec; 7(51):84388-84397. PubMed ID: 27768597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma.
    Rainusso N; Brawley VS; Ghazi A; Hicks MJ; Gottschalk S; Rosen JM; Ahmed N
    Cancer Gene Ther; 2012 Mar; 19(3):212-7. PubMed ID: 22173710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Review of T-Cell Related Therapy for Osteosarcoma.
    Yoshida K; Okamoto M; Aoki K; Takahashi J; Saito N
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32664248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adoptive immunotherapy of cancer using ex vivo expanded human gammadelta T cells: A new approach.
    Dokouhaki P; Han M; Joe B; Li M; Johnston MR; Tsao MS; Zhang L
    Cancer Lett; 2010 Nov; 297(1):126-36. PubMed ID: 20537791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. γδ T-cell immunotherapy for lung cancer.
    Yoshida Y; Nakajima J; Wada H; Kakimi K
    Surg Today; 2011 May; 41(5):606-11. PubMed ID: 21533930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Auto T cells expressing chimeric antigen receptor derived from auto antibody might be a new treatment for osteosarcoma.
    Weibo P; Zhaoming Y
    Med Hypotheses; 2012 May; 78(5):616-8. PubMed ID: 22330890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetically modified T-cell therapy for osteosarcoma.
    DeRenzo C; Gottschalk S
    Adv Exp Med Biol; 2014; 804():323-40. PubMed ID: 24924183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. γδ T cells in cancer immunotherapy.
    Zou C; Zhao P; Xiao Z; Han X; Fu F; Fu L
    Oncotarget; 2017 Jan; 8(5):8900-8909. PubMed ID: 27823972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.